前列地尔治疗急性脑梗死患者的效果

Effects of Alprostadil in treatment of patients with acute cerebral infarction

目的:观察前列地尔治疗急性脑梗死患者的效果。方法:选取2019年5月至2021年5月80例急性脑梗死患者进行前瞻性研究,按照随机数字表法分为观察组与对照组各40例。对照组给予常规溶栓治疗,观察组在对照组基础上给予前列地尔注射液治疗,比较两组临床疗效、美国国立卫生研究院卒中量表(NIHSS)评分、改良Rankin量表(mRS)评级、Barthel指数(BI)评分和治疗期间不良反应发生率。结果:观察组治疗总有效率为95.00%,明显高于对照组的77.50%,差异有统计学意义(P<0.05);治疗后,两组NIHSS评分均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05);治疗后,两组mRS评级均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05);治疗后,两组BI评分均高于治疗前,且观察组高于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:在常规溶栓治疗基础上采用前列地尔治疗急性脑梗死患者可提高治疗总有效率和BI评分,降低NIHSS评分和mRS评级,效果优于单纯常规溶栓治疗。

Objective:To observe effects of Alprostadil in treatment of patients with acute cerebral infarction.Methods:80 patients with acute cerebral infarction from May 2019 to May 2021 were selected for the prospective study,and were divided into observation group and control group according to the random number table method,40 cases in each.The control group was given routine thrombolytic therapy,while the observation group was given Alprostadil injection on the basis of that of the control group.The clinical efficacy,the National Institutes of Health Stroke Scale(NIHSS)score,the modified Rankin Scale(mRS)score,the Barthel Index(BI)score and the incidence of adverse reactions during the treatment were compared between the two groups.Results:The total effective rate of the observation group was 95.00%,which was significantly higher than 77.50%of the control group,and the difference was statistically significant(P<0.05).After the treatment,the NIHSS scores of the two groups were lower than those before the treatment,that of the observation group was lower than that of the control group,and the difference was statistically significant(P<0.05).After the treatment,the mRS scores of the two groups were lower than those before the treatment,that of the observation group was lower than that of the control group,and the difference was statistically significant(P<0.05).After the treatment,the BI scores of the two groups were higher than those before the treatment,that of the observation group was higher than that of the control group,and the difference was statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:On the basis of routine thrombolytic therapy,Alprostadil in the treatment of the patients with acute cerebral infarction can improve the total effective rate and the BI score,and reduce the NIHSS score and mRS score.Moreover,it is superior to single routine thrombolytic therapy.